Akebia Therapeutics, Inc.
$1.43
▼
-2.13%
2026-04-21 05:12:00
www.akebia.com
NCM: AKBA
Explore Akebia Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$381.73 M
Current Price
$1.43
52W High / Low
$4.08 / $1.14
Stock P/E
—
Book Value
$0.12
Dividend Yield
—
ROCE
11%
ROE
64.49%
Face Value
—
EPS
$-0.02
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
194
Beta
0.37
Debt / Equity
609.57
Current Ratio
1.55
Quick Ratio
1.46
Forward P/E
-14.74
Price / Sales
1.59
Enterprise Value
$388.97 M
EV / EBITDA
14.26
EV / Revenue
1.65
Rating
Strong Buy
Target Price
$4.4
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Leverage is relatively high.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Aquestive Therapeutics, Inc. | $4.24 | — | $527.23 M | — | -62.98% | 178.61% | $7.55 / $2.12 | $-0.28 |
| 2. | Alpha Teknova, Inc. | $2.91 | — | $157.01 M | — | -17.67% | -22.83% | $7.48 / $1.91 | $1.28 |
| 3. | Biofrontera Inc. | $1.09 | — | $12.81 M | — | -68.08% | -1.41% | $1.19 / $0.54 | $0.9 |
| 4. | Cardiol Therapeutics Inc. | $1.51 | — | $230.46 M | — | -162.05% | -1.59% | $2.17 / $1.23 | $0.08 |
| 5. | Viatris Inc. | $14.78 | — | $17.2 B | 3.23% | 0.84% | -21.08% | $16.47 / $7.39 | $12.78 |
| 6. | Akanda Corp. | $3.42 | — | $1.89 M | — | -102.48% | -60.86% | $209.03 / $2.29 | $22.67 |
| 7. | Cronos Group Inc. | $2.76 | — | $1.4 B | — | -1.7% | -0.26% | $4.66 / $2.35 | $2.87 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 57.62 M | 58.77 M | 62.47 M | 57.34 M | 46.5 M | — |
| Operating Profit | -8.55 M | 4.45 M | 14.09 M | 13.51 M | -14.31 M | — |
| Net Profit | -12.24 M | 0.54 M | 0.25 M | 6.11 M | -22.8 M | — |
| EPS in Rs | -0.05 | 0 | 0 | 0.02 | -0.09 | -0.1 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 236.2 M | 160.18 M | 194.62 M | 292.48 M |
| Operating Profit | 23.5 M | -50.41 M | -46.08 M | -64.85 M |
| Net Profit | -5.34 M | -69.41 M | -51.92 M | -94.23 M |
| EPS in Rs | -0.02 | -0.26 | -0.19 | -0.35 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 376.56 M | 220.67 M | 241.7 M | 356.05 M |
| Total Liabilities | 343.95 M | 269.86 M | 272.29 M | 350.82 M |
| Equity | 32.61 M | -49.19 M | -30.58 M | 5.23 M |
| Current Assets | 252.96 M | 113.83 M | 118.15 M | 185.18 M |
| Current Liabilities | 162.94 M | 80.91 M | 99.87 M | 129.54 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 67.99 M | -40.66 M | -23.38 M | -73.15 M |
| Investing CF | -7.93 M | -0.03 M | 0 M | -0.11 M |
| Financing CF | 72.93 M | 49.66 M | -25.21 M | 14.6 M |
| Free CF | 59.89 M | -40.69 M | -23.38 M | -73.27 M |
| Capex | -8.1 M | -0.03 M | — | -0.11 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -17.7% | -33.46% | — | — |
| Earnings Growth % | -33.67% | 44.89% | — | — |
| Profit Margin % | -43.33% | -26.68% | -32.22% | — |
| Operating Margin % | -31.47% | -23.67% | -22.17% | — |
| Gross Margin % | 60.56% | 61.9% | 70.74% | — |
| EBITDA Margin % | -8.57% | -4.25% | -13.96% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.